Class III β-tubulin shows unique expression patterns in a variety of neoplastic and non-neoplastic lymphoproliferative disorders

American Journal of Surgical Pathology

Volumn 34, Issue 5, 2010, Pages 645-655

  Yoon, Sun Och ^a,b   Kim, Wook Youn ^a,b   Go, Heounjeong ^a,b   Paik, Jin Ho ^a,b   Kim, Ji Eun ^c   Kim, Young A ^c   Huh, Joo R ^d   Jeon, Yoon Kyung ^a,b   Kim, Chul Woo ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

Author keywords

Class III tubulin; Follicular dendritic cell; Hodgkin lymphoma; Lymphoproliferative disorder; Non Hodgkin lymphoma

Indexed keywords

EID: 77951800247     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181d5d903     Document Type: Article

References (14)

1. Dumontet C, Jaffrezou JP, Tsuchiya E, et al. Resistance to microtubule-targeted cytotoxins in a K562 leukemia cell variant associated with altered tubulin expression and polymerization. Bull Cancer. 2004;91:E81-E112. (Pubitemid 38963967)
2. Ferrandina G, Zannoni GF, Martinelli E, et al. Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res. 2006;12: 2774-2779. (Pubitemid 43752116)
3. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103: 275-282.
4. Kang J, Lee I. TuJ1 (class III beta-tubulin) as phenotypic marker of lymphatic and venous valves. Cardiovasc Pathol. 2006;15:218-221. (Pubitemid 44038394)
5. Katsetos CD, Herman MM, Mork SJ. Class III beta-tubulin in human development and cancer. Cell Motil Cytoskeleton. 2003;55: 77-96.
6. Kavallaris M, Tait AS, Walsh BJ, et al. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res. 2001;61:5803-5809. (Pubitemid 32769098)
7. Laurent C, Meggetto F, Brousset P. Human herpesvirus 8 infections in patients with immunodeficiencies. Hum Pathol. 2008;39:983-993. (Pubitemid 351833114)
8. Lee S, Choi K, Ahn H, et al. TuJ1 (class III beta-tubulin) expression suggests dynamic redistribution of follicular dendritic cells in lymphoid tissue. Eur J Cell Biol. 2005;84:453-459. (Pubitemid 40353082)
9. Pasquier E, Kavallaris M. Microtubules: a dynamic target in cancer therapy. IUBMB Life. 2008;60:165-170.
10. Seve P, Lai R, Ding K, et al. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res. 2007;13:994-999. (Pubitemid 46340378)
11. Swerdlow SH, Campo E, Harris NL, et al. eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008;312-319; discussion 322-334.
12. Verrills NM, Flemming CL, Liu M, et al. Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interactions. Chem Biol. 2003;10:597-607. (Pubitemid 36940936)
13. Wright CW, Rumble JM, Duckett CS. CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells. J Biol Chem. 2007;282:10252-10262.
14. Yoon SO, Jeon YK, Paik JH, et al. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type. Histopathology. 2008;53:205-217.